Our approach is designed to improve testing efficiency when compared with multiple, single-biomarker tests1The Roche Foundation Medicine platform leverages next-generation sequencing (NGS) technology to examine regions of the tumour genome that common diagnostic techniques such as PCR/IHC/FISH, and multigene hotspot NGS tests may miss.2–11 Comprehensive genomic profiling (CGP) detects the four main classes of genomic alterations–base substitutions, insertions and deletions, copy number alterations and gene rearrangements–in a comprehensive set of over 300 cancer‑relevant genes, and reports tumour mutational burden (TMB) and microsatellite instability (MSI).*2,6,7,12,13–17
How is CGP different to existing diagnostic tests?
Multigene hotspot NGS tests
Comprehensive genomic profiling
The FoundationOne® report provides clear, detailed information to support treatment
Our clear, detailed report supports clinical decision-making by providing insights into the patient’s genomic profile and using these to inform the use of immunotherapies, identify alternative therapy options and identify trial opportunities. The Roche Foundation Medicine report (FoundationOne CDx) may also highlight important disease-relevant genes that have no alterations but are particularly relevant for the specific tumour type,17 and identify approved targeted therapies, which are constantly assessed and monitored for safety and efficacy.18,19